The U.S. Food and Drug Administration (FDA) has granted uniQure’s AMT-060, an investigational gene therapy, breakthrough therapy designation for patients with severe hemophilia B. The regulatory agency based its decision on data from the ongoing, dose-ranging Phase 1/2 clinical trial (NCT02396342) evaluating AMT-060 for hemophilia B. The study’s estimated completion date…
Search results for:
Belief Biomed is launching a Phase 1/2 clinical trial in China to test BBM-H901, its investigational one-time gene therapy for hemophilia B. The announcement comes after China’s National Medical Products Administration (NMPA) approved the company’s investigational new drug application, which had been submitted in April, Belief Biomed said in…
When you infuse through a port there are several steps to completing an infusion, as opposed to a peripheral stick. Having all the supplies together and prepared and opened in a certain order to maintain good, sterile technique helps make the process move along quickly. Especially when you…
When my oldest son was diagnosed with severe hemophilia at birth, I found myself catapulted into a world I never knew existed. I became part of the bleeding disorder community, like it or not. I slowly began to realize that this community was filled with passionate, well-educated people who knew…
Many hemophilia B patients experience joint pain, depression and overall poor health, a study reports. Other findings were that women with hemophilia B had worse health than men and that those caring for children with the disorder often experience anxiety and depression. The team titled its study in the European Journal…
At 28 weeks pregnant, it seems I have entered my “nesting” phase. Two days ago, my husband Jared and I chanced upon a good deal for a crib. We had no intentions of getting a crib then, but by a stroke of serendipity, we ended up with one anyway.
Inadequate access to treatment centers, lack of expert care, and high bleeding rates lead to similar joint complications in hemophilia patients with and without inhibitors, and joint problems in 70% of the people taking part in a recent study in five developing countries. The research, “HAEMOcare:…
The Royal College of Surgeons in Ireland (RCSI) and Bayer will collaborate to develop improved treatments for patients with severe hemophilia. The research collaboration will focus on personalized treatments adapted to the severity of each patient’s condition to achieve safer and more effective blood clotting in hemophilia…
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on uniQure’s gene therapy program for hemophilia B, which includes AMT-061 (etranacogene dezaparvovec), due to a possibly related serious adverse event in one patient. The event concerns a preliminary diagnosis of hepatocellular carcinoma (HCC), a form…